In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aldeyra Therapeutics, Inc.

http://www.aldeyra.com/

Latest From Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Eyes First Line Market As Phase II Dry Eye Candidate Impresses

The firm’s lead asset, reproxalap, one-upped Novartis’s Xiidra in a mid-stage ophthalmology study, signalling its first-line promise in a market ridden with compliance issues.

Clinical Trials Ophthalmic

Aldeyra Looking At Paths To Approval In Dry Eye After Phase III Miss

Firm revises second Phase III trial for co-primary endpoints, possibly improving its chances of success for demonstrating efficacy on a sign of dry eye disease. Initial Phase III study missed ocular redness measure.

Clinical Trials Drug Approval Standards

Finance Watch: Roivant To Go Public In SPAC Merger, Raise $611m

Public Company Edition: Roivant’s deal sets its market cap at $7.3bn. Beyond the Werewolf and Vaccitech offerings, more drug developers are slated to go public during the first week of May. And in follow-on offerings, COMPASS Pathways raises $144m and Aldeyra brings in $125m.

Finance Watch Deals

Aldeyra Allergic Conjunctivitis Drug Has Good Prospects With Phase III Results

The company announced positive results for reproxalap from its Phase III INVIGORATE trial in allergic conjunctivitis, which may be a good sign for its dry eye disease studies.

Clinical Trials Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Aldexa Therapeutics, Inc.
    • Helio Vision, Inc.
    • Neuron Systems, Inc.
UsernamePublicRestriction

Register